A Phase 2 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-01-27.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.
Among the 29 studies testing febuxostat in Gout, this one is the 14th largest by enrollment, is one of 2 that started in 2001, is one of 9 in phase 2, and was the 4th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 109 across the 29 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 29 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Gout by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Gout by Takeda, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2001, is one of 5 in phase 2, and was the 4th registered.
Takeda’s Gout studies by the year they started, since 2001.
1 of the studies testing febuxostat in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing febuxostat in Gout, from their registry updates:
Among Takeda’s 15 in Gout:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 milligrams per deciliter [mg/dL]), is a common biochemical abnormality. Aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often not sufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or in part of uric acid crystals. Management of gout requires chronic treatment aimed at lowering serum urate into a subsaturating range (usually \<6.0 mg/dL) in which crystal formation and deposition are prevented or reversed.
Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.
Subjects who want to participate in this study will have successfully completed study TMX-00-004 (NCT00174967).
All participants will initially receive an 80 mg dose. Dose titrations will occur in order to obtain and maintain clinically acceptable serum urate levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Febuxostat
Drug: Febuxostat
Drug: Febuxostat
Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
Also known as: TMX-67, Tei-6720, Uloric
Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
Also known as: TMX-67, Tei-6720, Uloric
Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
Also known as: TMX-67, Tei-6720, Uloric
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.
Time frame: Month 6
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.
Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.
Time frame: Month 12
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.
Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 18 visit was summarized.
Time frame: Month 18
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.
Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.
Time frame: Month 24
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.
Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.
Time frame: Month 36
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.
Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 48 visit was summarized.
Time frame: Month 48
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.
Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 60 visit was summarized.
Time frame: Month 60
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.
The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
Time frame: Last Visit on treatment (up to 66 months).
Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.
Time frame: Baseline and Month 6
Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.
Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized.
Time frame: Baseline and Month 12
Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.
Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized.
Time frame: Baseline and Month 18
Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.
Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized.
Time frame: Baseline and Month 24
Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.
Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized.
Time frame: Baseline and Month 36
Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.
Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized.
Time frame: Baseline and Month 48
Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.
The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation.
Time frame: Baseline and Month 60
Percent Change in Serum Urate Levels From Baseline at Final Visit.
The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
Time frame: Baseline and Last Visit on treatment (up to 66 months).
Subjects were enrolled at 23 investigational sites in the United States from 21 March 2001 to 29 December 2006
| Milestone | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Started | 8 | 79 | 29 | 116 |
| Completed | 6 | 41 | 11 | 58 |
| Not completed | 2 | 38 | 18 | 58 |
| Withdrew: Adverse event | 1 | 10 | 2 | 13 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 2 | 5 |
| Withdrew: Personal reason(s) | 0 | 14 | 8 | 22 |
| Withdrew: Gout flare | 0 | 4 | 4 | 8 |
| Withdrew: Reason not specified | 1 | 6 | 2 | 9 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit. | 50 | 93 | 65 | 82 |
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Month 6 Visit. | -35.9 ± 9.55 | -50.6 ± 9.84 | -47.6 ± 19.6 | -48.3 ± 13.07 |
Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit. | 57 | 85 | 67 | 79 |
Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 18 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit. | 50 | 82 | 57 | 74 |
Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit. | 63 | 76 | 92 | 77 |
Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit. | 67 | 84 | 92 | 84 |
Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 48 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit. | 83 | 92 | 85 | 90 |
Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 60 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit. | 100 | 93 | 91 | 93 |
The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit. | 100 | 82 | 81 | 83 |
Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Month 12 Visit. | -35.0 ± 13.16 | -49.7 ± 9.26 | -49.3 ± 15.77 | -48.3 ± 11.94 |
Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Month 18 Visit. | -35.5 ± 16.35 | -48.7 ± 11.12 | -39.5 ± 19.36 | -45.4 ± 14.35 |
Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Month 24 Visit. | -38.9 ± 19.41 | -46.7 ± 11.59 | -54.7 ± 12.02 | -47.3 ± 13.24 |
Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Month 36 Visit. | -43.0 ± 9.14 | -46.9 ± 13.35 | -56.4 ± 13.76 | -48.4 ± 13.6 |
Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Month 48 Visit. | -50.0 ± 4.16 | -50.3 ± 10.61 | -53.8 ± 16.41 | -51.1 ± 11.64 |
The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Month 60 Visit. | -45.5 ± 8.70 | -51.1 ± 13.21 | -59.0 ± 18.74 | -52.0 ± 14.32 |
The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total Febuxostat |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline at Final Visit. | -49.2 ± 7.10 | -47.1 ± 16.42 | -50.7 ± 19.12 | -48.1 ± 16.61 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat 40 mg QD | — | 3/12 (25%) | 5/12 (41.7%) |
| Febuxostat 80 mg QD | — | 14/116 (12.1%) | 44/116 (37.9%) |
| Febuxostat 120 mg QD | — | 4/37 (10.8%) | 9/37 (24.3%) |
| Febuxostat Total | — | 21/116 (18.1%) | 53/116 (45.7%) |
| Event | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Febuxostat Total |
|---|---|---|---|---|
| Intestinal Ulcers & Perforation not elsewhere classified (NEC)Gastrointestinal disorders | 1/12 | 0/116 | 0/37 | 1/116 |
| Cholecystitis and CholelithiasisHepatobiliary disorders | 1/12 | 1/116 | 0/37 | 2/116 |
| Lower Respiratory Tract and Lung InfectionsInfections and infestations | 1/12 | 1/116 | 0/37 | 2/116 |
| Spine and Neck DeformitiesMusculoskeletal and connective tissue disorders | 1/12 | 0/116 | 0/37 | 1/116 |
| Central Nervous System Hemorrhages & Cerebrovascular AccidentsNervous system disorders | 1/12 | 0/116 | 0/37 | 1/116 |
| Depressive DisordersPsychiatric disorders | 1/12 | 0/116 | 0/37 | 1/116 |
| Bladder and Urethral SymptomsRenal and urinary disorders | 1/12 | 0/116 | 0/37 | 1/116 |
| Supraventricular ArrhythmiasCardiac disorders | 0/12 | 5/116 | 0/37 | 5/116 |
| Cerebral Injuries NECInjury, poisoning and procedural complications | 0/12 | 0/116 | 1/37 | 1/116 |
| Fractures and Dislocations NECInjury, poisoning and procedural complications | 0/12 | 0/116 | 1/37 | 1/116 |
| Event | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Febuxostat Total |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/12 | 9/116 | 1/37 | 10/116 |
| Hyperlipidaemias NECMetabolism and nutrition disorders | 1/12 | 3/116 | 0/37 | 4/116 |
| Renal LithiasisRenal and urinary disorders | 1/12 | 2/116 | 0/37 | 3/116 |
| Rashes, Eruptions and ExanthemsSkin and subcutaneous tissue disorders | 1/12 | 2/116 | 0/37 | 3/116 |
| ArthropathiesMusculoskeletal and connective tissue disorders | 1/12 | 1/116 | 0/37 | 2/116 |
| Blood Amylase IncreasedInvestigations | 1/12 | 0/116 | 0/37 | 1/116 |
| Liver Function AnalysesInvestigations | 0/12 | 4/116 | 2/37 | 6/116 |
| Muscle PainsMusculoskeletal and connective tissue disorders | 0/12 | 0/116 | 2/37 | 2/116 |
| Gastrointestinal Atonic and Hypomotility Disorders NECGastrointestinal disorders | 0/12 | 5/116 | 0/37 | 5/116 |
| Headaches NECNervous system disorders | 0/12 | 5/116 | 0/37 | 5/116 |
| Age, Customized(Subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| <45 years | 2 | 20 | 9 | 31 |
| 45 to <65 years | 4 | 40 | 15 | 59 |
| ≥65 years | 2 | 19 | 5 | 26 |
| Age Continuous(years) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| Mean | 54.5 ± 11.44 | 53.9 ± 12.85 | 51.3 ± 13.01 | 53.3 ± 12.74 |
| Sex: Female, Male(Participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| Female | 0 | 9 | 2 | 11.0 |
| Male | 8 | 70 | 27 | 105.0 |
| History of Kidney Stone(Subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| Yes | 0 | 11 | 3 | 14 |
| No | 8 | 68 | 26 | 102 |
| Presence of Tophus(Subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| Yes | 1 | 13 | 12 | 26 |
| No | 7 | 66 | 17 | 90 |
| Race/Ethnicity(Subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 2 | 2 |
| Black or African American | 1 | 5 | 3 | 9 |
| White | 7 | 71 | 21 | 99 |
| Hispanic | 0 | 2 | 1 | 3 |
| Other | 0 | 1 | 2 | 3 |
| Renal Function(Subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| Normal | 3 | 33 | 12 | 48 |
| Impaired | 5 | 46 | 17 | 68 |
| Urine Uric Acid(Subjects) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Total |
|---|---|---|---|---|
| Underexcretor | 5 | 62 | 21 | 88 |
| Overproducer | 3 | 16 | 7 | 26 |
| Missing | 0 | 1 | 1 | 2 |
2 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Mar 2001, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat